Monte Rosa Therapeutics Reports Positive MRT-8102 Phase 1 Study Results
Monte Rosa Therapeutics announced positive results from its Gforce-1 Phase 1 study for MRT-8102, demonstrating normalization of key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) in subjects with elevated cardiovascular disease risk.
Story updates
11:09:03 AM UTC
SquawkNews
Monte Rosa Therapeutics reported Phase 1 data showing MRT-8102 reduced multiple ASCVD-related biomarkers to levels comparable to healthy volunteers and was well tolerated over four weeks. Phase 2 studies in CAD, gout, and hidradenitis suppurativa are planned starting as early as Q4 2026.Material De…